Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
68.1M
-
Shares change
-
-75.7K
-
Total reported value, excl. options
-
$103M
-
Value change
-
-$1.4M
-
Number of buys
-
14
-
Number of sells
-
-25
-
Price
-
$1.51
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q3 2019
54 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q3 2019.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.1M shares
of 1.57B outstanding shares and own 4.33% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (28M shares), NEA Management Company, LLC (15.8M shares), Capital World Investors (6.79M shares), BAILLIE GIFFORD & CO (4.16M shares), Man Group plc (2.05M shares), WELLINGTON MANAGEMENT GROUP LLP (1.6M shares), FMR LLC (1.58M shares), ORBIMED ADVISORS LLC (1.35M shares), MILLENNIUM MANAGEMENT LLC (914K shares), and RENAISSANCE TECHNOLOGIES LLC (879K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.